Remicade (infliximab), a new biotech drug for Crohn's disease
October 1998
Centocor will market Remicade (infliximab), a new biotech drug for Crohn's disease.
It's a monoclonal antibody that neutralizes the activity of tumor necrosis factor...a protein that promotes inflammation.
Remicade is also being tested for other inflammatory conditions such as rheumatoid arthritis.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote